Dr Michael Tse-yin Lu, MD | |
55 Fruit St, Massachusetts General Hospital, Department Of Radiology, Boston, MA 02114-2621 | |
(161) 724-9729 | |
Not Available |
Full Name | Dr Michael Tse-yin Lu |
---|---|
Gender | Male |
Speciality | Diagnostic Radiology |
Experience | 17 Years |
Location | 55 Fruit St, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013242098 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | A 107408 (California) | Secondary |
2085R0202X | Radiology - Diagnostic Radiology | 250734 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Massachusetts General Hospital | Boston, MA | Hospital |
Newton-wellesley Hospital | Newton, MA | Hospital |
North Shore Medical Center - | Salem, MA | Hospital |
Wentworth-douglass Hospital | Dover, NH | Hospital |
Martha's Vineyard Hospital Inc | Oak bluffs, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.
In a post in Management Sciences for Health's (MSH) "Global Health Impact" blog, Jonathan Quick, president and CEO of MSH, interviews Sylvia Vriesendorp, technical lead on leadership at MSH, about Kenya's First National Conference on Health Leadership, Management and Governance, which took place in February and "demonstrated the long-term vision of the Kenyans who are running the health system."
"Students are blindfolded for a period of about one hour," she said. "It really demonstrates how much we take for granted – suddenly activities such as eating and socialising become difficult and exhausting. There is always at least one dinner guest who feels they can't cope and has to remove their blindfold."
› Verified 4 days ago
Entity Name | Massachusetts General Physicians Organization Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.
In a post in Management Sciences for Health's (MSH) "Global Health Impact" blog, Jonathan Quick, president and CEO of MSH, interviews Sylvia Vriesendorp, technical lead on leadership at MSH, about Kenya's First National Conference on Health Leadership, Management and Governance, which took place in February and "demonstrated the long-term vision of the Kenyans who are running the health system."
"Students are blindfolded for a period of about one hour," she said. "It really demonstrates how much we take for granted – suddenly activities such as eating and socialising become difficult and exhausting. There is always at least one dinner guest who feels they can't cope and has to remove their blindfold."
› Verified 4 days ago
Entity Name | The General Hospital Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.
In a post in Management Sciences for Health's (MSH) "Global Health Impact" blog, Jonathan Quick, president and CEO of MSH, interviews Sylvia Vriesendorp, technical lead on leadership at MSH, about Kenya's First National Conference on Health Leadership, Management and Governance, which took place in February and "demonstrated the long-term vision of the Kenyans who are running the health system."
"Students are blindfolded for a period of about one hour," she said. "It really demonstrates how much we take for granted – suddenly activities such as eating and socialising become difficult and exhausting. There is always at least one dinner guest who feels they can't cope and has to remove their blindfold."
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Michael Tse-yin Lu, MD 55 Fruit St, Massachusetts General Hospital, Department Of Radiology, Boston, MA 02114-2621 Ph: () - | Dr Michael Tse-yin Lu, MD 55 Fruit St, Massachusetts General Hospital, Department Of Radiology, Boston, MA 02114-2621 Ph: (161) 724-9729 |
News Archive
Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.
A long non-coding RNA (lincRNA) - called lincRNA-EPS - responsible for regulating innate immunity has been identified by a team of scientists at the University of Massachusetts Medical School.
Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.
In a post in Management Sciences for Health's (MSH) "Global Health Impact" blog, Jonathan Quick, president and CEO of MSH, interviews Sylvia Vriesendorp, technical lead on leadership at MSH, about Kenya's First National Conference on Health Leadership, Management and Governance, which took place in February and "demonstrated the long-term vision of the Kenyans who are running the health system."
"Students are blindfolded for a period of about one hour," she said. "It really demonstrates how much we take for granted – suddenly activities such as eating and socialising become difficult and exhausting. There is always at least one dinner guest who feels they can't cope and has to remove their blindfold."
› Verified 4 days ago
Jennifer Michelle Thomas, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Department Of Radiology, Boston, MA 02115 Phone: 617-732-6248 | |
Dr. Meghavi Mashar, MB BCHIR Radiology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Rafeeque A Bhadelia, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Bidmc Wcc90, Boston, MA 02215 Phone: 617-754-2058 Fax: 617-754-2004 | |
Dr. Srinivasan Mukundan Jr., M.D. Radiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Brigham And Women's Hospital, Boston, MA 02115 Phone: 617-732-7260 | |
Raymond W Liu, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Grb 293, Boston, MA 02114 Phone: 917-923-2079 | |
Dr. Hillary R. Kelly, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Grb-273a, Boston, MA 02114 Phone: 617-726-8320 Fax: 617-724-3338 | |
Dr. Tina Young Poussaint, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6450 |